<p>Bayer AG has published the transcript of its Q3 2025 Investor Call, held on November 12, 2025, to discuss the company’s third quarter results. The event was attended by key members of Bayer’s leadership, including the CEO, the Head of Investor Relations, and divisional presidents. During the call, Bayer’s management highlighted that the company remains on track to deliver its full-year guidance, with sales “slightly up in currency and portfolio adjusted terms both in the quarter and year-to-date.” Core EPS reached EUR 4.29, marking a 7% increase from the previous year, while free cash flow stood at negative EUR 800 million, which was described as “in line with our projections and the seasonality of our business.” Management also discussed divisional performance, noting resilience in the Crop Science segment despite regulatory challenges, and reported rapid uptake of new medicines in the pharmaceutical division. One executive stated, “Today the medicine is off to a strong start, already exceeding our ambitions for 2025,” and highlighted that the product had reached around 50% market share in new-to-brand prescriptions in Germany within months of launch. Additionally, Bayer announced that Judith Hartmann will join as CFO in March 2026, succeeding the current Chief Financial Officer in June. The full transcript can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

BAYN

<p>Bayer AG Publishes Transcript of Q3 2025 Investor Call</p>